Navigation Links
Increasing Diagnosis Rates and Growing Use of Key Agents Such as Pfizer's Lyrica Will Drive Eight Percent Annual Growth in the Fibromyalgia Drug Market Through 2018
Date:7/13/2009

WALTHAM, Mass., July 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increased use of key agents such as Pfizer's Lyrica, Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeristar/Ariclaim and Forest Laboratories/Cypress Bioscience's Savella will drive eight percent annual growth in the fibromyalgia market through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Fibromyalgia also finds that improved diagnosis of the disorder and an expanding drug-treated population will be major market drivers over the next decade, particularly in the U.S. where the greatest growth in diagnosis rates is expected to occur. In the world's major markets, the U.S. accounted for nearly 80 percent of fibromyalgia drug sales in 2008 and will continue to account for more than two-thirds of fibromyalgia drug sales through 2018. Expansion of the market in Europe and Japan will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder.

"Uptake of Lyrica and Cymbalta/Xeristar/Ariclaim will be limited in Europe because both agents received a negative opinion from European regulatory authorities for approval for fibromyalgia," said Decision Resources Analyst Andrea Buurma, B.A. "Although the decision for Savella has not been made yet, regulators' initial refusal to recommend Lyrica's and Cymbalta's marketing authorizations for fibromyalgia indicates more rigorous standards in this region -- it is not clear whether Savella will be able to meet these standards."

The report also finds that, owing to its status as the first-ever approved agent for fibromyalgia and its favorable safety and tolerability profile, Lyrica will remain the dominant U.S. patient and market share leader through 2018 for fibromyalgia treatment. In the U.S., nearly half of the drug-treated fibromyalgia population received Lyrica in 2008, and this patient share will not change through 2018.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Fibromyalgia: Assessing Current and Future Opportunities in an Expanding Drug-Treated Population. This webinar will be held on Tuesday, July 28 at 2 p.m. EDT. For more information, please contact Gisselle Morales at 781-296-2691 or email her at gmorales@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563
    ccomfort@dresources.com          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency
2. Planning for 2020: increasing elderly population poses huge challenges in cancer care
3. US hospitals report infections increasing in frequency and cost
4. Increasing young adult smoking linked to smoking in movies
5. Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
6. New Report: Increasing Oregons Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
7. New Report: Increasing Marylands Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
8. Increasing genetic diversity of HIV in the US
9. Studies Show Importance of Language Services on Reducing Disparities, Increasing Quality of Patient Care
10. Kidney Disease Increasing in U.S.
11. Generic Prescription Drugs Show Increasingly Greater Use in Southeastern Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: